ArticlePharmacoEconomics - open2021
Costs of Respiratory Syncytial Virus Hospitalizations in Colombia.
Article in PharmacoEconomics - open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Economic burden of respiratory syncytial virus disease in Latin America: A systematic review.Human vaccines & immunotherapeutics · 2024Pooled it
- Respiratory syncytial virus disease burden in children and adults from Latin America: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.BMC medicine · 2023Pooled it
- Economic burden of respiratory syncytial and parainfluenza viruses in children of upper-middle-income countries: a systematic review.Jornal de pediatriaPooled it
- Economic and health burden of severe respiratory syncytial virus infection among hospitalised children at three tertiary hospitals in Argentina, Brazil, and Colombia: a two-year prospective multicentre cohort study.Lancet regional health. Americas · 2026Article
- Co-design and evaluation of a regional and rural translation bronchiolitis platform: study protocol.Pediatric research · 2026Article
- Direct medical costs of respiratory infections in adults: A multicenter retrospective analysis in Thai Nguyen, Vietnam.PloS one · 2026Article
- Cost of respiratory syncytial virus hospitalisation in Brazilian infants: a micro-costing study from the perspective of a Brazilian tertiary public hospital, 2020-2023.BMC public health · 2025Article
- Economic Burden of Respiratory Syncytial Virus Infection in Colombia: A Nationwide Cost-of-Illness Study.Journal of health economics and outcomes research · 2025Article
- Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.BMC infectious diseases · 2024Article
- Overuse of medications in low- and middle-income countries: a scoping review.Bulletin of the World Health Organization · 2023Article
- Usefulness of C-Reactive Protein and Clinical Characteristics in Identifying Severe Bacterial Infection in Children with Fever without Source.Turkish archives of pediatrics · 2022Article
- Impact of the updating of clinical guidelines for RSV bronchiolitis on the use of diagnostic testing and medications in tertiary hospitals in Colombia.The Pan African medical journal · 2022Article
- TLR4 Gene Polymorphisms Interaction WithFrontiers in pediatrics · 2022Article
- The cost-utility of early use of high-flow nasal cannula in bronchiolitis.Health economics review · 2021Article
- [Predictors of hospitalization plus airway support among infants with recurrent wheezing in the emergency department].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Article
- Budget impact analysis of surfactant therapy for bronchiolitis in critically ill infants: the Colombian National Health System perspective.BMC health services research · 2021Article
- Inappropriate antibiotic prescribing for acute bronchiolitis in Colombia: a predictive model.Journal of pharmaceutical policy and practice · 2021Article
- Importance of respiratory syncytial virus as a predictor of hospital length of stay in bronchiolitis.F1000Research · 2021Article
- Disability-adjusted life years for acute bronchiolitis in infants in Colombia.The Pan African medical journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral clinical practice guidelines exist for the management of respiratory syncytial virus (RSV) infection, but the use and overuse of medications and medical tests with insufficient evidence of effectiveness remains substantial.
objectiveThis study aimed to evaluate the medical costs associated with bronchiolitis hospitalizations caused by RSV infection among infants aged < 2 years in Colombia.
methodsThis was a prevalence-based cost-of-illness multicentric study performed from the societal perspective during 2016-2017. A case was defined as a laboratory-confirmed RSV infection with hospitalization. All costs and use of resources were collected directly from medical invoices and health records.
resultsThis study included 193 patients with a diagnosis of RSV. The average hospital stay duration was 5.55 days. The major contributors to hospitalization costs were room costs (31.5%), drugs (21.8%), and indirect costs (14.9%). Medications with the highest costs were nebulization with a hypertonic solution and systemic antibiotics. In total, 96% of β-lactam antibiotics, 90% of bronchodilators, and 86% of corticosteroids and epinephrine were classified as inappropriate.
conclusionRSV infection in Colombia places a high economic burden on the health system. Generating comprehensive data on healthcare resource use and costs associated with RSV will help to provide valuable information for the development of cost-effectiveness models and to guide RSV-prevention strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.